代謝領域における共同研究およびライセンシング契約：2019年～2024年

当レポートでは、代謝領域の共同研究およびライセンシング案件について調査し、2019年以降の契約動向、代謝領域の共同研究およびライセンシング案件、ベンチマーク分析- 取引の市場価値、財務条件、主な取引額、最も活発なディールメーカーなどについてまとめています。

目次

エグゼクティブサマリー

第1章 -イントロダクション

第2章 代謝領域取引の動向

• イントロダクション
• 代謝領域での長年の提携動向
• 代謝領域の提携、取引タイプ別
• 代謝領域の提携、産業分野別
• 代謝領域の提携、開発段階別
• 代謝領域の提携、技術タイプ別
• 代謝領域の提携、治療適応症別

第3章 -代謝領域提携に関する金融取引条件

• イントロダクション
• 代謝領域の提携に関する公開された財務条件
• 代謝領域の提携のヘッドライン値
• 代謝領域の取引の前払い
• 代謝領域の取引のマイルストーンペイメント
• 代謝領域の取引のロイヤルティ率

第4章 -主要な代謝領域取引と取引担当者

• イントロダクション
• 代謝領域との提携が最も活発
• 代謝領域で最も活発なディールメーカーのリスト
• 代謝領域の取引額上位

第5章 -代謝領域契約文書ディレクトリ

• イントロダクション
• 契約書が入手可能な代謝領域提携取引

第6章 治療ターゲット別代謝領域の取引

• イントロダクション
• 代謝領域治療標的別の取引
• 取引ディレクトリ
• 取引ディレクトリ- 代謝領域取引、企業別（2019年～2024年）
• 取引ディレクトリ- 代謝領域取引、技術タイプ別（2019年～2024年）
• 取引タイプの定義
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• Current Partneringからの最近のレポートタイトル

Metabolic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the metabolic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 547 metabolic deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in metabolic dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the metabolic field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in metabolic dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of metabolic deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of metabolic deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in metabolic deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Metabolic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse metabolic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Metabolic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of metabolic trends and structure of deals entered into by leading biopharma companies worldwide.

Metabolic Collaboration and Licensing Deals includes:

• Trends in metabolic dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of metabolic deal records covering pharmaceutical and biotechnology
• The leading metabolic deals by value
• Most active metabolic licensing dealmakers

In Metabolic Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Metabolic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

• 2.1. Introduction
• 2.2. Metabolic partnering over the years
• 2.3. Metabolic partnering by deal type
• 2.4. Metabolic partnering by industry sector
• 2.5. Metabolic partnering by stage of development
• 2.6. Metabolic partnering by technology type
• 2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for metabolic partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for metabolic partnering
• 3.3. Metabolic partnering headline values
• 3.4. Metabolic deal upfront payments
• 3.5. Metabolic deal milestone payments
• 3.6. Metabolic royalty rates

Chapter 4 - Leading metabolic deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in metabolic partnering
• 4.3. List of most active dealmakers in metabolic
• 4.4. Top metabolic deals by value

Chapter 5 - Metabolic contract document directory

• 5.1. Introduction
• 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by metabolic therapeutic target
• Deal directory
• Deal directory - Metabolic deals by company A-Z 2019 to 2024
• Deal directory - Metabolic deals by technology type 2019 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Metabolic partnering since 2019
• Figure 2: Metabolic partnering by deal type since 2019
• Figure 3: Metabolic partnering by industry sector since 2019
• Figure 4: Metabolic partnering by stage of development since 2019
• Figure 5: Metabolic partnering by technology type since 2019
• Figure 6: Metabolic partnering by indication since 2019
• Figure 7: Metabolic deals with a headline value
• Figure 8: Metabolic deals with upfront payment values
• Figure 9: Metabolic deals with milestone payment
• Figure 10: Metabolic deals with royalty rates
• Figure 11: Active metabolic dealmaking activity since 2019
• Figure 12: Top metabolic deals by value since 2019